CHIH


MSCI China Health Care ETF

Reasons to Consider CHIH

Targeted Exposure

CHIH is a targeted play on the Health Care Sector in China – the world’s second largest economy by GDP.

ETF Efficiency

In a single trade, CHIH delivers access to dozens of health care companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.

All Share Exposure

The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings, among others.

Key Information As of 10/21/21

Inception Date 12/07/18
Total Expense Ratio 0.65%
Net Assets $17.27 million
NAV $25.78
Fact Sheet

ETF Summary

The Global X MSCI China Health Care ETF (CHIH) seeks to invest in large- and mid-capitalization segments of the MSCI China Index that are classified in the Health Care Sector as per the Global Industry Classification System (GICS).

ETF Objective

The Global X MSCI China Health Care ETF (CHIH) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI China Health Care 10/50 Index.

Trading Details As of 10/21/21

Ticker CHIH
Bloomberg Index Ticker NU722071
CUSIP 37954Y541
ISIN US37954Y5419
Primary Exchange NYSE Arca
Shares Outstanding 670,002
Number of Holdings 91
30-Day Median Bid-Ask Spread 1.18%

Distributions As of 10/21/21

30-Day SEC Yield 0.15%
Distribution Frequency Semi-Annually

ETF Prices As of 10/21/21

NAV $25.78 Daily Change -$0.32 -1.22%
Market Price $25.80 Daily Change -$0.32 -1.21%

Performance History

As of recent month & quarter-end (09/30/21)
As of recent month & quarter-end (09/30/21)
Fund NAV Market Price Index
1 Year 12.96% 12.18% 13.75%
Since Inception 22.85% 22.90% 23.76%
1 Year 12.96% 12.18% 13.75%
Since Inception 22.85% 22.90% 23.76%
Year-to-Date -1.45% -0.34% -0.99%
1 Month 0.95% 1.18% 1.01%
3 Months -19.40% -19.12% -19.28%
Since Inception 78.47% 78.68% 82.27%
Year-to-Date -1.45% -0.34% -0.99%
1 Month 0.95% 1.18% 1.01%
3 Months -19.40% -19.12% -19.28%
Since Inception 78.47% 78.68% 82.27%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 10/21/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
9.16 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 14.55 108,680 1,581,120.27
8.75 BGNE BEIGENE LTD-ADR BYYWPW6 375.28 4,027 1,511,252.56
5.51 1801 HK INNOVENT BIOLOGICS INC BGR6KX5 9.89 96,200 951,599.23
5.25 1093 HK CSPC PHARMACEUTI 6191997 1.11 817,208 906,134.25
4.26 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 0.77 958,400 735,993.21
4.01 ZLAB ZAI LAB LTD-ADR BD9GVY0 99.72 6,950 693,054.00
3.93 2359 HK WUXI APPTEC CO LTD-H BGHH0L6 21.75 31,176 678,135.80
3.50 241 HK ALIBABA HEALTH BRXVS60 1.62 373,300 605,035.99
2.83 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 4.12 118,700 489,363.33
2.52 1066 HK SHANDONG WEIG-H 6742340 1.78 244,300 434,294.35
2.19 1099 HK SINOPHARM GROUP CO-H B3ZVDV0 2.75 137,400 377,343.86
2.13 300760 C2 SHENZHEN MINDR-A BHQK864 56.99 6,461 368,230.42
1.92 603259 C1 WUXI APPTEC CO LTD-A BHWLWV4 22.11 15,024 332,107.86
1.91 853 HK MICROPORT SCIENTIFIC CORP B676TW7 5.13 64,200 329,503.93
1.83 1833 HK PING AN HEALTHCA BDRYVB3 6.89 45,900 316,468.25
1.80 600276 C1 JIANGSU HENGRU-A BP3R369 7.91 39,272 310,479.75
1.74 HCM HUTCHMED CHINA-ADR BYXV9H7 32.17 9,352 300,853.84
1.74 600436 C1 ZHANGZHOU PIEN-A BP3R7Z6 67.93 4,426 300,649.13
1.73 3692 HK HANSOH PHARMACEU BJYKB72 2.53 118,300 299,476.33
1.62 867 HK CHINA MEDICAL SY B6WY993 1.87 150,300 280,336.50
1.50 2196 HK FOSUN PHARMA-H B8XBQ96 4.96 52,400 259,841.40
1.50 300015 C2 AIER EYE HSPTL-A BD5CLQ4 7.29 35,524 259,047.99
1.38 3759 HK PHARMARON BEIJ-H BK72QD3 21.06 11,350 238,999.62
1.28 300122 C2 CHONGQING ZHIF-A BD5CJY8 22.90 9,633 220,615.03
1.20 3347 HK HANGZHOU TIGER-H BMZC7F8 18.99 10,920 207,329.77
1.13 1951 HK JINXIN FERTILITY BJ9JY53 1.66 117,700 195,004.66
1.12 6185 HK CANSINO BIOLOGICS INC-H BJKDJS2 28.35 6,800 192,784.97
1.09 2607 HK SHANGHAI PHARM-H B4Q4CJ6 1.93 97,400 187,932.93
1.01 IMAB I-MAB-SPONSORED ADR BKRRKY7 67.00 2,608 174,736.00
1.01 570 HK TRAD CHI MED 6971779 0.49 359,100 174,606.29
0.94 1530 HK 3SBIO INC BY9D3L9 0.97 166,200 161,623.86
0.86 000538 C2 YUNNAN BAIYAO-A BD5CP95 14.72 10,110 148,777.72
0.78 9926 HK AKESO INC BLFJ7Y1 5.83 23,000 134,170.73
0.70 300347 C2 HANGZHOU TIGER-A BD5CCK5 26.04 4,616 120,197.46
0.66 3320 HK CHINA RESOURCES BYNGG26 0.50 229,500 113,656.97
0.66 600196 C1 SHANGHAI FOSUN-A BP3R3M5 7.96 14,274 113,608.32
0.64 000661 C2 CHANGCHUN HIGH-A BD5CDB3 43.71 2,528 110,497.23
0.62 2005 HK SSY GROUP LTD BYP9J68 0.50 213,500 107,106.33
0.58 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 9.33 10,700 99,836.40
0.57 000963 C2 HUADONG MEDICINE CO LTD-A BD5CM94 5.27 18,711 98,627.72
0.56 002821 C2 ASYMCHEM LABOR-A BD6V5C4 63.36 1,513 95,856.22
0.54 300759 C2 PHARMARON BEIJ-A BK4XYC4 29.84 3,100 92,510.08
0.52 300896 C2 IMEIK TECHNOLO-A BNR4MY3 98.84 900 88,955.25
0.52 2500 HK VENUS MEDTECH -H BL6V047 5.23 17,000 88,891.89
0.46 300601 C2 SHENZHEN KANGT-A BFY8HT2 17.43 4,543 79,193.92
0.45 600763 C1 TOPCHOICE MEDI-A BYYFJH8 36.00 2,180 78,481.57
0.45 600332 C1 GUANGZHOU BAIY-A BP3R4Q6 4.66 16,559 77,225.99
0.44 002001 C2 ZHEJIANG NHU CO LTD-A BD5CH66 4.14 18,240 75,499.69
0.40 603392 C1 BEIJING WANTAI-A BMXTWX4 36.56 1,900 69,469.21
0.35 002007 C2 HUALAN BIOLOGI-A BD5CL19 4.64 13,070 60,606.55
0.35 600998 C1 JOINTOWN PHARMACEUTICAL-A BP3R541 2.57 23,370 59,964.82
0.31 000423 C2 DONG-E-E-JIAOCO LTD-A BD5CM61 6.96 7,800 54,253.76
0.31 300595 C2 OVCTEK CHINA INC-A BHQPSJ2 10.66 5,024 53,553.99
0.31 002044 C2 MEINIAN ONEHEA-A BD73L10 1.15 45,920 52,838.21
0.30 300003 C2 LEPU MEDICAL TECHNOLOGY-A BD5CM16 4.04 12,901 52,148.10
0.28 002422 C2 SICHUAN KELUN-A BD5CL08 2.83 17,000 48,091.24
0.27 002294 C2 SHENZHEN SALUBRIS PHARM-A BD5CM05 4.17 11,200 46,710.14
0.26 BNR BURNING ROCK-ADR BMBKH34 13.18 3,395 44,746.10
0.25 600867 C1 TONGHUA DONGBA-A BP3R808 1.72 25,305 43,458.21
0.25 300529 C2 JAFRON BIOMEDI-A BFY8H03 8.27 5,200 43,015.51
0.25 600161 C1 BEIJING TIAN-A BP3R9J4 5.03 8,400 42,252.16
0.24 603858 C1 SHANDONG BUCHA-A BYW5NC3 2.89 14,487 41,821.37
0.24 603882 C1 GUANGZHOU KING-A BFYX689 15.34 2,700 41,423.68
0.22 000739 C2 APELOA PHARMA-A BD5LY17 6.15 6,100 37,520.68
0.21 601607 C1 SHANG PHARM -A BP3R4Z5 2.94 12,600 37,005.16
0.20 603707 C1 NANJING KING-F-A BF2DZL7 5.59 6,136 34,293.55
0.20 603127 C1 JOINN LABORATO-A BK94819 24.31 1,400 34,033.17
0.19 002223 C2 JIANGSU YUYUE-A BD5CJM6 5.39 6,100 32,860.44
0.19 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 13.15 2,433 32,002.48
0.18 300558 C2 BETTA PHARMACE-A BD6QWL7 13.00 2,420 31,460.21
0.18 002603 C2 SHIJIAZHUANG Y-A BD5CHJ9 2.54 12,027 30,596.35
0.17 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.02 28,800 29,441.81
0.17 600079 C1 HUMANWELL HEAL-A BP3R712 3.19 9,200 29,338.49
0.17 603456 C1 ZHEJIANG JIUZH-A BMQBVL8 7.73 3,700 28,603.01
0.16 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 8.61 3,223 27,751.21
0.16 300253 C2 WINNING HEALTH-A BD5CKZ6 2.06 13,470 27,730.15
0.15 000999 C2 CHINA RESOURCE-A BD5CL42 4.32 6,000 25,934.42
0.15 600521 C1 ZHEJIANG HUAHA-A BP3RBR6 2.70 9,510 25,711.76
0.14 300677 C2 INTCO MEDICAL-A BMTCVT6 8.43 2,850 24,017.52
0.13 002030 C2 DAAN GENE CO LTD-A BD5CKW3 3.00 7,560 22,688.34
0.12 CASH 1.00 20,474 20,385.81
0.12 688185 C1 CANSINO BIOLOGICS INC-A BMD9JD3 47.60 417 19,850.37
0.12 002019 C2 YIFAN PHARMACE-A BD5CDK2 2.36 8,400 19,791.32
0.11 600511 C1 CHINA NATIONAL-A BP3R9B6 4.76 4,000 19,043.00
0.11 000513 C2 LIVZON PHARM-A BD5CQ25 5.57 3,400 18,943.74
0.11 603658 C1 AUTOBIO DIAGNO-A BYW5N89 8.06 2,282 18,391.33
0.10 000623 C2 JILIN AODONG P-A BD5CLG4 2.62 6,700 17,527.10
0.10 600380 C1 JOINCARE PHARM-A BP3RBV0 1.73 10,100 17,424.56
0.09 002399 C2 SHENZHEN HEPAL-A BD5CKT0 2.40 6,700 16,079.62
0.08 600529 C1 SHANDONG PHAR-A BMVB2W1 4.49 3,200 14,372.73
0.08 300482 C2 GUANGZHOU WOND-A BFY8GZ1 5.99 2,390 14,315.34
0.08 300463 C2 MACCURA BIOTECH CO LTD-A BD5M283 4.29 3,000 12,873.28
Holdings are subject to change.

ETF Characteristics As of 10/21/21

Return on Equity 9.50%
Weighted Avg. Market Cap 11,086 M
2020 2021
Price-to-earnings 63.28 42.00
Price-to-book value 4.13 3.89

Source: AltaVista Research, LLC

ETF Risk Stats As of 10/21/21

Versus Beta
S&P 500 0.52
MSCI EAFE 0.49
MSCI Emg. Mkts 0.77
Standard Deviation 25.60%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHIH is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by MSCI, nor does MSCI make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with MSCI.